(Q42356099)

28 October 2017

Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients (English)

1 reference

28 October 2017

1 reference

1 reference

Mayumi Negishi

1

1 reference

28 October 2017

Kenju Shimomura

2

1 reference

28 October 2017

Peter Proks

3

1 reference

28 October 2017

Yohnosuke Shimomura

4

1 reference

28 October 2017

Masatomo Mori

5

1 reference

28 October 2017

language of work or name

English

0 references

publication date

30 April 2008

1 reference

British Journal of Clinical Pharmacology

28 October 2017

1 reference

28 October 2017

66

1 reference

28 October 2017

2

1 reference

28 October 2017

318-319

1 reference

Miglitol, a new alpha-glucosidase inhibitor

28 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2492932

Efficacy of troglitazone on body fat distribution in type 2 diabetes

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18507653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18507653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18507653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2008.03216.X

1 reference

28 October 2017

1 reference

28 October 2017

PubMed publication ID

18507653

1 reference